Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(50.0%)

N/A

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 2(2)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04975178Phase 3Recruiting

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

Role: collaborator

NCT03187366Not ApplicableUnknown

Schistosomiasis in Senegal

Role: collaborator

NCT03767946Completed

Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal

Role: lead

NCT03799510Phase 2Completed

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

Role: collaborator

NCT03041766Phase 2Completed

Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

Role: collaborator

NCT01553552Completed

Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal

Role: lead

NCT01545115Completed

Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal

Role: lead

All 7 trials loaded